trial of clodronate in multiple myeloma . Br J Haematol 2001 ; 113 : 1035 – 1043 . 30. Rosen LS Gordon D Kaminski M . Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic
Rashmi Chugh
evaluating zoledronic acid in patients with newly diagnosed metastatic osteosarcoma in a single-arm trial (NCT00742924). This study has the goal of determining the safety and maximum tolerated dose of zoledronic acid when administered with standard cytotoxic
Use of Zoledronic Acid in Early-Stage Breast Cancer Harnden Kathleen MD Blackwell Kimberly MD 4 2015 13 13 4 4 480 480 486 486 0130480 10.6004/jnccn.2015.0061 Surgical Management of De Novo Stage IV Breast Cancer Patrick Jilma
- Apr 2015
John Charlson, Elizabeth C. Smith, Alicia J. Smallwood, Purushottam W. Laud and Joan M. Neuner
is unknown whether these women were previously diagnosed with osteoporosis and were already on therapy. It is also noted that since our study period, evidence has accumulated supporting the use of zoledronic acid and denosumab as adjuvant cancer
Charles P. Borden, Charles L. Shapiro, Maria Teresa Ramirez, Linda Kotur and William Farrar
involvement. Of the cases with antiresorptive agents administered, 71% involved zoledronic acid and 29% involved denosumab. The 8% nonconcordant cases represented 4 patients. For 3 of these patients, antiresorptive agents were “considered but not given” but
Harold J. Burstein
;10:425–426) that noted that 3 bone-modifying agents (denosumab, zoledronic acid, and pamidronate) were all endorsed by NCCN and ASCO guidelines. Yet these agents differ markedly in logistics and cost. Are they really all equally preferred? On what grounds? At
William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice Lyons, P. Kelly Marcom, Jennifer Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica S. Young, Jennifer L. Burns and Rashmi Kumar
compression, and hypercalcemia of malignancy. The NCCN panel recommends treatment with a bone-modifying agent such as zoledronic acid, pamidronate, or denosumab (category 1) in addition to chemotherapy or endocrine therapy if bone metastasis is present
Dawn Goetz
local oncologist to treat the metastatic disease. He began treatment with leuprolide injections every 3 months; bicalutamide, 50 mg daily; and zoledronic acid monthly. After several months of leuprolide and bicalutamide, his PSA plateaued at 11.6 ng
James Mohler, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony D'Amico, James A. Eastham, Charles A. Enke, Daniel George, Eric Mark Horwitz, Robert P. Huben, Philip Kantoff, Mark Kawachi, Michael Kuettel, Paul H. Lange, Gary MacVicar, Elizabeth R. Plimack, Julio M. Pow-Sang, Mack Roach III, Eric Rohren, Bruce J. Roth, Dennis C. Shrieve, Matthew R. Smith, Sandy Srinivas, Przemyslaw Twardowski and Patrick C. Walsh
-controlled study of 106 men with prostate cancer, intravenous zoledronic acid every 3 months increased bone mineral density of the hip and spine by a difference of 3.9% and 7.8%, respectively. 106 Similar results have been reported with annual zoledronic acid. 107
the results of a study comparing denosumab and zoledronic acid (Zometa, Novartis Oncology) finding denosumab to be at least as efficacious as zoledronic acid in preventing skeletal-related events. Dr. Carlson emphasized the importance of biomarkers
